Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2018

View Archived Issues

Anti-IL-23 therapy with mirikizumab shows activity in ulcerative colitis trial

FDA grants QIDP designation to PLG-0206 as a treatment for prosthetic joint infection

Anti-IL-15 monoclonal antibody AMG-714 shows proof-of-concept in celiac disease trials

EMA grants PRIME designation to AT-132 for the treatment of X-linked myotubular myopathy

FDA grants approval for a new indication for Alimta

Initial phase Ib results of Hu5F9-G4 with rituximab in relapsed/refractory NHL

First clinical data reported for PLX-9486 in GIST, solid tumors

Korea Research Institute of Chemical Technology identifies DAPK2 inhibitors

Hookipa and Gilead to collaborate on development of immunotherapies against HIV and hepatitis B

Phase II data demonstrate elenbecestat treatment leads to significant effect on Abeta in the brain

MONALEESA-3, CDK4/6 inhibition with ribociclib in the de novo metastatic breast cancer setting

Ionis and Biogen close strategic collaboration to develop antisense drugs for neurological diseases

Spyryx presents positive data for first cohort of HOPE-1 phase II trial of SPX-101

Navitor Pharmaceuticals divulges mTOR complex 1 and glucose transport inhibitors

AbbVie seeks Japanese approval for Humira in hidradenitis suppurativa

FDA provides feedback for phase III program of efgartigimod in myasthenia gravis

Kyowa Hakko Kirin, Leo Pharma launch Dovobet gel new formulation for psoriasis vulgaris in Japan

Independent DMC completes last intermediate review of SCiStar study of AST-OPC1

Axovant licenses gene therapy for Parkinson's disease from Oxford BioMedica

Nimbus Therapeutics announces new financing

EZH2 inhibitors patented by Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology

Amgen identifies new apelin receptor agonists

Cognition Therapeutics doses first patient in SNAP study of Elayta

Merck & Co. describes DGAT-2 inhibitors

First patient enrolled in phase IIa study of THX-110